Innovation in Development of Dermatologic Drugs Approved by the FDA

Dermatologic drug development in the US has remained disproportionately low compared with other therapeutic classes due to lower revenue potential and benefit-to-risk ratios. 1 ,2 Only 5 new drugs for diseases treated primarily by dermatologists were approved by the US Food and Drug Administration (FDA) between 1999 and 2009. 1 However, over the past decade, opportunities for innovation in dermatologic drug development may have changed. This cross-sectional study characterized the frequency and degree of innovation of new dermatologic drugs approved by the FDA from 2012 to 2022.